Phio Pharmaceuticals
PHIO
3 hedge funds and large institutions have $2.04M invested in Phio Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 1 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
25% less funds holding
Funds holding: 4 → 3 (-1)
35% less capital invested
Capital invested by funds: $3.14M → $2.04M (-$1.09M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$176K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$176K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$328K |
| 2 |
BC
Broadfin Capital
New York
|
-$176K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BC
1
Broadfin Capital
New York
| $1.35M | -$176K | -1 | -11% |
|
|
2
Renaissance Technologies
New York
| $257K | +$176K | +1 | +100% |
|
|
3
Vanguard Group
Malvern,
Pennsylvania
| $247K | +$176K | +1 | +100% |
|
4
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $56K | – | – | – |
|
|
VKH
5
Virtu KCG Holdings
New York
| $43K | – | – | – |
|
|
BIT
6
BlackRock Institutional Trust
San Francisco,
California
| $29K | – | – | – |
|
7
Citadel Advisors
Miami,
Florida
| $25K | – | – | – |
|
8
UBS Group
Zurich,
Switzerland
| $6K | – | – | – |
|
9
Bank of America
Charlotte,
North Carolina
| $5K | – | – | – |
|
10
Goldman Sachs
New York
| $5K | – | – | – |
|
|
BFA
11
BlackRock Fund Advisors
San Francisco,
California
| $4K | – | – | – |
|
|
PSUF
12
People's United Financial
Bridgeport,
Connecticut
| $4K | – | – | – |
|
|
TSS
13
Two Sigma Securities
New York
| $4K | – | – | – |
|
14
Northern Trust
Chicago,
Illinois
| $3K | – | – | – |
|
15
Geode Capital Management
Boston,
Massachusetts
| $71 | – | – | – |
|
|
AFM
16
Anson Funds Management
Dallas,
Texas
| – | -$328K | -1 | Closed |
|
PHIO Hedge Fund Activity: Q1 2016 in Review
3 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q1 2016, worth a combined $2.04M — down 35% from $3.14M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of PHIO and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 2 added.
The largest buyer was Renaissance Technologies, adding an estimated $176K. The largest seller was Anson Funds Management, exiting entirely with an estimated $328K sold.
- 3 institutional investors held Phio Pharmaceuticals (PHIO) as of Q1 2016, down from 4 in Q4 2015.
- Funds reported $2.04M of Phio Pharmaceuticals stock for Q1 2016, down 35% quarter-over-quarter.
- 0 funds opened new Phio Pharmaceuticals positions in Q1 2016 and 1 closed out, a net change of -1 holder.
- The largest Phio Pharmaceuticals buyer in Q1 2016 was Renaissance Technologies, an estimated $176K added.
- The largest Phio Pharmaceuticals seller in Q1 2016 was Anson Funds Management, an estimated $328K sold.
Based on aggregated 13F filings for Q1 2016.